Vaxcell-Bio Therapeutics Co., Ltd.
323990.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$100.69B
Close$
Share Statistics
| Market cap | $100.69 Billion |
|---|---|
| Enterprise Value | $96.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-577.4 |
| Beta | 0.43 |
| Outstanding Shares | 23,173,887 |
Return
| Return on Equity | -28.00% |
|---|---|
| Return on Assets | -25.42% |
| Return on Invested Capital | -28.85% |
Valuation & Multiples
| P/E Ratio | -6.76 |
|---|---|
| PEG | -115.18 |
| Price to Sales | 14.96 |
| Price to Book Ratio | 1.82 |
| Enterprise Value to Revenue | 14.85 |
| Enterprise Value to EBIT | -6.07 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Vaxcell-Bio Therapeutics Co., Ltd.
81 employees
CEO: Jae-Jung Lee Established in 2010, Vaxcell-Bio Therapeutics Co., Ltd. specializes in the research, development, and commercialization of immune cell-based therapies designed to treat cancer, primarily operating within South Korea. The company's main base of operations is located in Hwasun-eup, South Korea.